Jazz Pharmaceuticals Inc. Third Quarter Earnings Sneak Peek

Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ) will unveil its latest earnings on Tuesday, November 1, 2011. Jazz Pharmaceuticals is a specialty pharmaceutical company, which is focused on developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.

Jazz Pharmaceuticals, Inc. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for profit of 84 cents per share, a rise of more than twofold from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved up from 74 cents. Between one and three months ago, the average estimate moved up. It has dropped from 87 cents during the last month. For the year, analysts are projecting net income of $3.08 per share, a rise of more than twofold from last year.

Past Earnings Performance: The company has beaten estimates the last four quarters and is coming off a quarter where it topped forecasts by 6 cents, reporting profit of 75 cents per share against a mean estimate of net income of 69 cents per share.

Investing Insights: Here’s Why Chipotle’s Stock Keeps Winning.

Wall St. Revenue Expectations: On average, analysts predict $72 million in revenue this quarter, a rise of 61% from the year ago quarter. Analysts are forecasting total revenue of $269.8 million for the year, a rise of 55.2% from last year’s revenue of $173.8 million.

Analyst Ratings: Analysts are bullish on this stock with five analysts rating it as a buy, none rating it as a sell and none rating it as a hold.

A Look Back: In the second quarter, the company swung to a profit of $33.2 million (71 cents a share) from a loss of $6.4 million (18 cents) a year earlier, beating analyst estimates. Revenue rose 59.5% to $64.6 million from $40.5 million.

Key Stats:

The company has enjoyed double-digit year-over-year percentage revenue growth for the past four quarters. Over that span, the company has averaged growth of 47.2%, with the biggest boost coming in the most recent quarter when revenue rose 59.5% from the year earlier quarter.

Competitors to Watch: Cephalon, Inc. (NASDAQ:CEPH), Forest Laboratories, Inc. (NYSE:FRX), Transcept Pharmaceuticals, Inc. (NASDAQ:TSPT), Pfizer Inc. (NYSE:PFE), GlaxoSmithKline plc (NYSE:GSK), Eli Lilly & Co. (NYSE:LLY), Abbott Laboratories (NYSE:ABT), Caraco Pharmaceutical Laboratories Ltd. (AMEX:CPD), Watson Pharmaceuticals, Inc. (NYSE:WPI), and McKesson Corporation (NYSE:MCK).

Stock Price Performance: During September 28, 2011 to October 26, 2011, the stock price had dropped $5.04 (-11.6%) from $43.53 to $38.49. The stock price saw one of its best stretches over the last year between June 13, 2011 and June 23, 2011 when shares rose for nine-straight days, rising 19% (+$5.10) over that span. It saw one of its worst periods between May 9, 2011 and May 17, 2011 when shares fell for seven-straight days, falling 11.1% (-$3.39) over that span. Shares are up $18.81 (+95.6%) year to date.

(Source: Xignite Financials)

Investing Insights: Here’s Why Chipotle’s Stock Keeps Winning.